|

Osimertinib Clinical Trials

44 actively recruiting trials across 19 locations

No change since June 2026

Also known as: AZD 9291, AZD-9291, AZD9291, AZD9291, Tagrisso, Erlotinib, Gefitinib, Furmonertinib, Almonertinib etc. +6 more

Pipeline

Phase 1: 8Phase 2: 17Phase 3: 8Phase 1/2: 7Phase 2/3: 1

Top Sponsors

Memorial Sloan Kettering Cancer Center3
AstraZeneca3
TYK Medicines, Inc2
National Cancer Institute (NCI)2
Vivace Therapeutics, Inc1

Indications

Cancer44
Lung Cancer42
Non Small Cell Lung Cancer14
Stage IV Lung Cancer AJCC v85
NSCLC4

Other19 trials

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Phase 3

A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer

Phase 2

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

Phase 1

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

Phase 3

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy

Phase 2

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

Phase 2

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

Phase 3

ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

N/A

Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC

Phase 2

Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

Phase 2

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

Phase 2

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

Phase 2

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Phase 2

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Phase 3

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Phase 1/2

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Phase 2

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Phase 2

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Phase 2

Birmingham, Alabama3 trials

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1/2

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

University of Alabama at Birmingham

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

Anchorage, Alaska2 trials

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Anchorage Associates in Radiation Medicine

Phase 3

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Anchorage Associates in Radiation Medicine

Phase 2

Los Angeles, California2 trials

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Valkyrie Clinical Trials

Phase 1/2

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 2

Sacramento, California2 trials

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

University of California, Davis Comprehensive Cancer Center

Phase 1/2

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

UC Davis Cancer Center (Data Collection Only)

Phase 2

San Francisco, California2 trials

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

University of California, San Francisco

Phase 1

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

UCSF Helen Diller Family Comprehensive Cancer Center

Phase 1/2

Daphne, Alabama1 trial

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis

Phase 2

Fayetteville, Arkansas1 trial

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Research Site

Phase 3

Springdale, Arkansas1 trial

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Highlands Oncology Group - Springdale /ID# 277132

Phase 2/3

Beverly Hills, California1 trial

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Cedars-Sinai Cancer at Beverly Hills (THO)

Phase 1

Duarte, California1 trial

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

City of Hope Medical Center

Phase 2

Fountain Valley, California1 trial

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Research Site

Phase 3

Denver, Colorado1 trial

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Sarah Cannon Research Institute at HealthONE

Phase 1

Miami, Florida1 trial

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

BAPTIST ALLIANCE - MCI (Data Collection Only)

Phase 2

Atlanta, Georgia1 trial

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Emory University Hospital/Winship Cancer Institute

Phase 1

Indianapolis, Indiana1 trial

Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Phase 1/2

Lexington, Kentucky1 trial

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

University of Kentucky Chandler Medical Center

Phase 1

Calverton, Maryland1 trial

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Maryland Oncology Hematology

Phase 1

Basking Ridge, New Jersey1 trial

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Phase 1/2

Columbus, Ohio1 trial

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.